Everything you need to know about Pfizer's COVID-19 vaccine
This week, as COVID-19 cases continue to climb across the country, there is a glimmer of hope for returning to normal life: a vaccine. Pharmaceutical companies Pfizer and BioNTech say that results from a Phase 3 study of their vaccine candidate look promising and that immunity could last a year. Today, we hear from CBC science and technology reporter Emily Chung on what we know about the Pfizer-BioNTech vaccine that early results suggest is 90 per cent effective in preventing COVID-19.
Front Burner · CBC
November 11, 202023m 8s
Audio is streamed directly from the publisher (mgln.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
This week, as COVID-19 cases continue to climb across the country, there is a glimmer of hope for returning to normal life: a vaccine.
Pharmaceutical companies Pfizer and BioNTech say that results from a Phase 3 study of their vaccine candidate look promising and that immunity could last a year.
Today, we hear from CBC science and technology reporter Emily Chung on what we know about the Pfizer-BioNTech vaccine that early results suggest is 90 per cent effective in preventing COVID-19.